With market leadership in pain management and outstanding generic drug distribution capabilities, Endo is an ideal commercialization partner for our fentanyl patch
," said Robert C.
DiCosolo had more than 15 times the amount of fentanyl in her bloodstream than a properly functioning Duragesic fentanyl patch
was designed to provide.
The facts are that there was an extensive history of selling leaking Duragesic fentanyl patches
to the public; Janice DiCosolo's fentanyl patch
was recalled shortly after her death; the FDA found numerous deficiencies in the Duragesic manufacturing process; she died with 15 times the amount of fentanyl the patch was intended to deliver in her blood; and the Cook County medical examiner said fentanyl killed her.
An example is Amarin, which has multiple sales partners in Germany for its fentanyl patch
, each with its own product name.
9, 2008, hours after applying a fentanyl patch
manufactured by Corona, Calif.
42 Weighted average number of common shares outstanding: Basic 23,603 23,603 23,566 23,566 Diluted 23,861 23,861 23,981 23,981 (1) Non-GAAP amounts exclude adjustments associated with the earning and recognition of the remaining deferred license revenue as well as the write-off of pre-launch inventories related to Noven's developmental fentanyl patch
, net of applicable income taxes.
Net loss and diluted loss per share include a previously-announced charge associated with the write-off of existing inventories related to Noven's developmental fentanyl patch
(the "Inventory Charge") in the amount of $9.
licensee of Noven's fentanyl patch
, was also present at the meeting.
0 million, primarily due to an increase in non-clinical development expenses related to the fentanyl patch
Our developmental fentanyl patch
is intended to be the generic equivalent of Johnson & Johnson's Duragesic(R) product, and our Abbreviated New Drug Application is under review at the FDA," said Strauss.
If you would like more information on the fentanyl patch
case involving Adam Hendelson, please contact Mark Annick at 800-559-4534 (office), 214-213-1754 (mobile) or mark@legalpr.
At the AMCP conference, Prime will also be presenting results of additional studies involving the integration of medical and pharmacy data including clinical utilization management program opportunities for infliximab and the fentanyl patch